Reviewer's report

Title: Emerging Resistant gram-positive infections: Impact of glycopeptide use on length of stay

Version: 1 Date: 9 April 2006

Reviewer: Robert Sawyer

Reviewer's report:

General

---------------------------------------------------------------------------------------------------

Major Compulsory Revisions (that the author must respond to before a decision on publication can be reached)

Please add information regarding the reasons patients were not felt to be eligible for oral switch. We routinely switch even critically ill patients to oral therapy even in the presence of nasogastric suction, ileus, or bowel obstruction.

---------------------------------------------------------------------------------------------------

Minor Essential Revisions (such as missing labels on figures, or the wrong use of a term, which the author can be trusted to correct)

---------------------------------------------------------------------------------------------------

Discretionary Revisions (which the author can choose to ignore)

It would be give some general estimates of cost savings that could be realized with oral switch.

What next?: Unable to decide on acceptance or rejection until the authors have responded to the major compulsory revisions

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: No

Declaration of competing interests:

I have acted as a consultant for Pfizer who funded the study and produces linezolid.